FdaApplication
NDA 022023
Identifiers
- fda_app_no: NDA022023
Properties
| Property | Value |
|---|---|
| applicant_name | MERCK AND CO INC |
| application_type | NDA |
| approval_date | 2008-01-25 |
Revenue by product
EMEND
| Period | Revenue |
|---|---|
| Q4 2020 | $30.0M |
| Q3 2020 | $39.0M |
| Q2 2020 | $33.0M |
| Q1 2020 | $43.0M |
| Q4 2019 | $52.0M |
| Q3 2019 | $98.0M |
| Q2 2019 | $121.0M |
| Q1 2019 | $117.0M |
| Q4 2018 | $126.0M |
| Q3 2018 | $123.0M |
| Q2 2018 | $148.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| EMEND | FOSAPREPITANT DIMEGLUMINE | EQ 150MG BASE/VIAL | POWDER;INTRAVENOUS |
| EMEND | FOSAPREPITANT DIMEGLUMINE | EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | POWDER;INTRAVENOUS |
2 products